Background. For a subset of adults and children with primary focal segmental glomerulosclerosis (FSGS), proteinuria and renal dysfunction recur after kidney transplantation (KTx). Predicting recurrence and response to plasmapheresis (PP) or other interventions remains problematic. Methods. The prevalence, recurrence rate, outcomes, and treatment responses of patients with FSGS were determined among 1573 KTx recipients. Although 5.0% carried some diagnosis of FSGS, only 1.9% (nϭ30) met strict diagnostic criteria for primary FSGS including biopsy-proven FSGS, lack of secondary factors, negative family history, and progression to end-stage renal disease within 10 years. Results. Of these, 47% had recurrent FSGS compared with 8% of those not meeting strict criteria (PϽ0.001). Recurrence was more common in children compared with adults (86% vs. 35%, Pϭ0.01). Graft survival was lower for recipients with primary FSGS compared with all others and inferior graft survival was attributable to recurrent FSGS. Fourteen patients received PP preemptively (pre-KTx) or therapeutically (post-KTx) for recurrent disease. Four pediatric patients additionally received anti-CD20 (rituximab) therapy. Of the different treatment approaches, only PP combined with rituximab was associated with prolonged remission of proteinuria.
F ocal segmental glomerulosclerosis (FSGS) accounts for approximately 11% of childhood end-stage renal disease (ESRD) and, depending on age, 1% to 5% of adult ESRD in the United States (1) . Primary FSGS may relapse or recur after kidney transplantation (KTx) at a reported rate between 25% and 50% (2) (3) (4) (5) . The risk of relapse is particularly high (80%-90%) in those with a prior history of allograft loss due to recurrent FSGS. Risk may also be higher in pediatric KTx recipients and in those with treatment-resistant or rapidly progressive native kidney disease (2) (3) (4) (5) (6) . Recurrent FSGS after KTx exhibits a spectrum of severity varying from primary nonfunction to chronic proteinuria with slowly declining renal function and is associated with reduced graft survival (2) (3) (4) (5) (6) (7) (8) (9) .
With the emergence of evidence that a circulating "permeability factor" is responsible for glomerular injury in recurrent FSGS (10) , extracorporeal therapies such as plasmapheresis (PP) (11) and immunoadsorption (12) have gained a foothold in the clinical management of this condition despite the absence of controlled trials demonstrating a clear benefit for long-term graft survival. Retrospective evaluation of patients managed without PP do, however, indicate early graft failure rates as high as 80% and, as a result, PP is used as initial therapy for recurrent FSGS (13) (14) (15) (16) . Even with more widespread application of PP, relapse rates remain high and patients may become PP dependent (2-4, 6, 7) . Based on the existing case series, early initiation of PP after diagnosis portends a better prognosis (14 -16) and, during the past decade, some centers have reported the use of preemptive or prophylactic PP in children or adults felt to be at high risk for disease recurrence (17) (18) (19) (20) . More recently, a small number of cases have also been reported in which remission of post-KTx FSGS occurred after therapy with a B-cell depleting anti-CD20 antibody (rituximab) (21) (22) (23) (24) (25) (26) (27) (28) . At present, the true benefit of newer interventional strategies such as preemptive PP and rituximab therapy remain only partially defined. In the case of preemptive PP, some reports indicate trends toward a reduction in recurrence rates and a resulting improvement in graft survival benefit in high-risk patients (18 -20) . Based on such studies, there is an emerging perception that preemptive PP may be effective in the prevention of FSGS recurrence in some patients. In the case of rituximab therapy, the literature is currently confined to a small number of reported cases (21) (22) (23) (24) (25) (26) (27) (28) and the mechanism of action remains speculative (26) . Nevertheless, given the dearth of therapeutic options for this potentially devastating graft complication, this intervention has also generated considerable clinical interest.
In the current study, we examine, within a large recent KTx cohort, the recurrence rates, treatment responses, and overall outcomes for children and adults with unequivocally diagnosed primary nonfamilial FSGS that progressed to ESRD within 10 years of diagnosis. Our results demonstrate that patients at high risk for FSGS recurrence after KTx can be identified based on clinical details and that recurrent disease characteristically occurs rapidly and significantly reduces overall graft survival in both children and adults. Our experience with PP therapy does not support the conclusion that preemptive PP can prevent FSGS recurrence in living donor recipients. However, our more recent cases in which PP was combined with rituximab administration indicate that a carefully planned interventional regimen may enhance the likelihood of achieving prolonged remission of proteinuria after early disease recurrence.
MATERIALS AND METHODS

Case Identification and Review
Medical records of all patients receiving KTx at Mayo Clinic between January 2000 and September 2006 were reviewed for documented cause of renal failure. Medical record review and intent to publish the result was approved in advance by the Mayo Clinic Institutional Review Board. Kidney transplant recipients with a preexisting diagnostic record of "FSGS," "focal glomerulosclerosis," or "FSG" were reviewed in detail with emphasis on documented pretransplant clinical and family history, laboratory data, and histologic reports. Cases meeting predetermined criteria for rapidly progressive, nonfamilial, primary FSGS (see below) were formally entered into the study group. For these cases, comprehensive extraction and tabulation of data from the medical record before and after KTx were performed. Specific clinical indices and outcome events were also derived for a control group consisting of all KTx recipients not meeting study entry criteria using the Mayo Clinic Transplant Database. For graft outcome analysis, the control group excluded recipients of positive crossmatch or ABO blood group incompatible KTx.
Definitions
Patients with any pre-KTx FSGS were defined as having, at a minimum, a clinical note referring to biopsy proven or clinically suspected FSGS. Within this group, those with unequivocal, nonfamilial, primary FSGS were defined as having (a) nephrotic range proteinuria with a clearly documented native renal biopsy revealing focal and segmental glomerulosclerosis in the absence of any other diagnostic lesion. (b) No family history of proteinuric renal disease. (c) No suspected secondary cause for FSGS (including severe obesity, congenital urologic disease, HIV, and prior nephrectomy). A further subgroup assignment of rapidly progressive FSGS was defined by progression from initial clinical onset of FSGS to the need for renal replacement therapy (dialysis or transplantation) within 10 years or less. For the purposes of this study, pediatric KTx recipients were defined as those less than or equal to 21 years of age at the time of KTx, identifying a group with childhood FSGS. FSGS recurrence or relapse was defined as the occurrence of persistent proteinuria after KTx determined to be from the allograft rather than from native kidneys and confirmed by an allograft biopsy with diffuse podocyte foot process effacement on electron microscopy. Time of recurrence was designated as the post-KTx day on which abnormal proteinuria was first detected.
Preemptive PP was defined as treatment with one or more PP sessions during the week before living donor KTx with the intention of modifying risk or severity of recurrent FSGS. Therapeutic PP was defined as treatment with one or more PP sessions in the post-KTx period for the purpose of treating confirmed or suspected recurrent FSGS. In patients receiving any therapy for recurrent FSGS, complete response was defined as a reduction in urine protein excretion (measured as 24 hr total urine protein or urine albumin-to-creatinine ratio) to within normal limits, partial response was defined as a reduction in urine protein excretion to less than or equal to 50% of the peak post-KTx level of proteinuria, and no response was defined as lack of reduction in protein excretion by 50%.
Clinical Interventions
KTx immunosuppression consisted of rabbit antithymocyte globulin (Thymoglobulin) induction and maintenance oral therapy with tacrolimus (nϭ26) or sirolimus (nϭ4), mycophenolate mofetil, and prednisone. In some patients believed to be at high recurrence risk, elimination of native kidney proteinuria was carried out as a means to ensure accurate monitoring of post-KTx proteinuria or to minimize the features of nephrotic syndrome before transplantation. This was achieved by bilateral native nephrectomies 6 to 8 weeks before KTx or bilateral ureteral ligations performed at the time of KTx. The decision to perform nephrectomy or ureteral ligation was based on clinical judgment and was not part of a formal study. In all cases, the additional surgical procedures and their timing were discussed and agreed on in advance with the patient or, where appropriate, the patient's parents as part of the pretransplant planning and informed consent process. No complications related to bilateral nephrectomies or bilateral ureteral ligations were encountered. Individual PP sessions consisted of removal of a single plasma volume under partial heparin anticoagulation with replacement by 5% normal serum albumin. Patients undergoing surgery, biopsy, or other invasive procedures within 48 hr of PP were replaced partially with normal serum albumin and partially with fresh frozen plasma. Preemptive PP was administered on days Ϫ5, Ϫ3, and Ϫ1 pre-KTx. Therapeutic PP was typically administered daily for 3 to 7 days, then 3 days a week for 4 to 12 weeks, and thereafter at frequencies varying from twice weekly to monthly depending on the clinical response. The response to PP and other therapies was followed up by serial measurements of 24 hr urine total protein or morning urine albumin-to-creatinine ratio performed at frequencies varying from three times a week to once every month.
Rituximab (Rituxan) was administered to pediatric patients intravenously at doses of 375 mg/m 2 every 2 weeks for a total of two (nϭ3) or four (nϭ1) doses. Premedication for each dose consisted of intravenous methylprednisolone (20 -40 mg), oral antihistamine, and acetaminophen.
Statistical Analysis
Data are expressed as meansϮSD or median (range) unless stated otherwise. Death-censored graft survival was analyzed using Kaplan-Meier plots and the Log-rank test was used to compare groups of interest. Means between normally distributed continuous data were compared by Student's t test and analysis of variance if more than two groups were present. Nonparametric tests were used for continuous data not normally distributed. Chi-square was used to test noncontinuous variables. For all analyses, statistical significance was assigned at P less than 0.05.
RESULTS
Frequency of Unequivocal, Rapidly Progressing Primary FSGS and Recurrence
A total of 1573 adult and pediatric KTx were performed between January 2000 and September 2006 with 79 recipients (5.0%) having some prior diagnosis of FSGS (Table 1) . Of these, 38 (2.4% of the total) met criteria for biopsy-proven, primary FSGS and 30 (1.9%) progressed to ESRD within 10 years of initial FSGS diagnosis. This latter group, designated as having rapidly progressive, primary FSGS constituted the high-risk patient group of interest and had a recurrence rate of 46.7%. Primary FSGS meeting study entry criteria was more common among pediatric compared with adult KTx recipients (8.2% vs. 1.5%, Pϭ0.002) as was recurrent FSGS after KTx (86% vs. 35%, Pϭ0.01). Time from KTx to diagnosis of FSGS recurrence was similar for adult and pediatric recipients and typically occurred within 24 to 48 hr of KTx. The relationship between age and rate of recurrence was also examined by dividing the 30 high-risk transplant recipients into 4 separate age groups at the time of transplantation: less than or equal to 17 years, 18 to 39 years, 40 to 49 years, and more than or equal to 50 years. Recurrence rates for the four groups were 80% (4/5), 83% (5/6), 18% (2/11), and 38% (3/8), respectively, indicating that the age-associated increased risk of recurrence extends beyond the pediatric years into early and even mid-adulthood.
Among the 49 patients who did not meet study entry criteria, 4 (8.2%) were subsequently diagnosed with FSGS involving the transplant (PϽ0.001 compared with study group). Eight of the 49 had biopsy-proven primary FSGS with progression to ESRD longer than 10 years and, of these, 2 (25%) had recurrent FSGS. Of the remaining 41 KTx recipients, who were not confirmed as having primary FSGS based on chart review, only 2 (4.9%) went on to develop FSGS of the allograft.
Characteristics and Recurrence Rates of KTx Recipients With Rapidly Progressive, Primary FSGS
The characteristics of all KTx recipients identified as having biopsy-proven, primary FSGS with progression to ESRD within 10 years are outlined in Tables 2 and 3 . Comparisons are shown between the pediatric and adult populations (Table 2 ) and between those with and without FSGS recurrence (Table 3) . For the total cohort, mean age at KTx was 39Ϯ18 years (range, 5-68 years) and 24 (80%) recipients were white. Five patients, all adults, were retransplants with prior graft losses attributed to FSGS recurrence (nϭ3) and rejection (nϭ2). Treatment of the native disease with cyclosporine A (CsA) or cyclophosphamide was more common for pediatric recipients. The majority of patients received living donor kidneys but living-related donor source was more common in pediatric recipients. The mean number of HLA mismatches was, however, similar in both adult and pediatric groups and no patient received a zero antigen mismatch allograft. Tacrolimus-based maintenance immunosuppressive therapy was most common (87%). Of note, all four adult patients initially managed with sirolimus developed nephrotic range proteinuria requiring conversion to tacrolimus. Of these, three clearly had recurrent FSGS.
As shown in Table 3 , recipients with FSGS recurrence post-KTx were younger, had higher pre-KTx peak protein- Figure 1 illustrates death-censored graft survival among the 30 KTx recipients with rapidly progressive, primary FSGS compared with other recipients in the same time period. As shown, the FSGS group had inferior graft survival during the first 4 years after KTx (Fig. 1A) . However, recipients with primary FSGS who did not have recurrence post-KTx experienced graft survival similar to the control group (Fig. 1B) indicating that diminished graft survival in this group was attributable to recurrent FSGS. In total, 8 (28%) renal allografts were lost for reasons other than patient death; 7 (50%) in the recurrence group and 1 (6.7%) in the nonrecurrence group (Pϭ0.007), the latter being due to immediate thrombosis. Although FSGS recurrence was more prevalent among pediatric recipients, the reduced graft survival remained evident and was also attributable to recurrent disease when only adult recipients were considered (Fig. 1C, D) . Table 4 summarizes the characteristics, treatment details, and outcomes for 14 individual KTx recipients from the total cohort of 30 who received PP therapy directly before ("preemptive") or after ("therapeutic") KTx for recurrent disease. Seven patients (cases 1-7) received therapeutic PP alone for recurrent FSGS with initiation of PP between 1 and 315 days post-KTx. Case 7 also received rituximab. Another seven patients (cases 8 -14) received preemptive PP of which six (86%) had recurrent FSGS and continued to receive therapeutic PP post-KTx. Cases 12, 13, and 14 also received rituximab therapy. In total, four patients (all pediatric) received rituximab, which was administered early in 3 (7-63 days post-KTx) and later in 1 (982 days post-KTx during a prolonged PP-dependent remission). Although a detailed statistical analysis was precluded by the small number of cases there were five notable outcome trends among this group. (1) A complete or partial response to PP occurred at some time during post-KTx therapy in 9 of 13 (69%) recipients with recurrent FSGS but did not preclude subsequent poor outcome. (2) Outcomes for recipients managed with therapeutic PP alone were generally poor with three graft losses (2 that never functioned adequately) and three grafts with persistent nephrotic range proteinuria. 
Graft Outcomes of KTx Recipients With and Without Rapidly Progressive, Primary FSGS
Outcomes of Pediatric and Adult KTx Recipients With Primary FSGS Managed by Therapeutic or Preemptive PP Therapy With or Without Rituximab
DISCUSSION
This single-center study provides a number of clinically relevant insights into recent experiences with patients receiving KTx as treatment of renal failure caused by FSGS. By comparing graft survival for the study cohort with that of all other KTx recipients during the same time period, we confirm that inferior graft outcomes continue to be associated with this condition in both children and adults and are directly attributable to recurrent disease (6 -9). Given current trends toward more aggressive "management" of KTx practice to avoid the negative impact of lower-than-expected early graft survival (29) , this observation should be of immediate concern to those centers that remain committed to achieving optimal transplant results for this challenging patient group. The experiences reported here additionally clarify the importance of carefully defining the histologic and clinical details associated with a pretransplant diagnosis of FSGS to accurately understand subsequent outcomes and treatment responses, and to lay the groundwork for much-needed multicenter therapeutic trials (5) . Finally, by detailing the clinical courses of 14 KTx recipients treated with and without preemptive PP or rituximab, we provide a realistic profile of what may or may not be achievable with combinations of currently available interventions.
It is generally accepted that any KTx candidate with a documented history of FSGS must be evaluated with the risk of recurrent disease in mind (2-9). Nonetheless, there continue to be variable views and few defined guidelines regarding the optimal assessment and management of such risk at a programmatic level. The review presented here of our recent practice involved more than 1500 KTx and indicates that the medical record of more than 5% of recipients contained some indication of a diagnosis or clinical suspicion of FSGS. Inclusion of all such patients in the analysis would have produced substantially lower reported recurrence risk. Furthermore, application of a preemptive therapeutic protocol such as preKTx PP to a broader patient population could result in an inflated estimation of the benefit of such therapy to prevent recurrence. By narrowing our focus to a subset of recipients consistent with true primary disease (5), we show that clinical efforts to minimize the severity of recurrent FSGS can realistically be directed toward approximately 1.5% of adult and 8% of pediatric recipients. Based on our observations, we would emphasize the need for a consensus among transplant centers in classifying pretransplant FSGS. Although we intended to exclude familial forms of FSGS, this was performed on the basis of family history alone and, in the absence of genetic analyses, the modifying role of podocin and other podocyte protein mutations cannot be determined. The application of a strict definition also allowed for a relatively robust analysis of the differences between those patients who did and did not suffer FSGS recurrence after KTx. Strikingly, we find that the recurrence rate was 86% among the seven pediatric recipients who met our predefined study criteria. Although this observation places a strong emphasis on transplant planning by pediatric nephrologists and surgeons for their patients with confirmed primary FSGS, we also observed that the association between younger age and higher recurrence risk extended to a group of recipients aged between 18 and 39 years. Thus, younger adults with known primary FSGS should be equally viewed as a group at high risk of post-KTx recurrence. In addition to younger age, we also find that clinical details of the native disease such as ESRD despite treatment with CsA and high-peak urine protein excretion provide some additional guidance for assessing risk and comparing outcomes among reported series (4). Of some concern, living-related donor source and lower number of HLA mismatches were also associated with FSGS recurrence risk in this series. Our interpretation of this at present, however, is that the observation reflects a greater frequency of kidney donation by a parent or other family member to pediatric recipients rather than a true pathogenic link to HLA matching. This interpretation would be in keeping with existing reports drawn from large databases (8, 9) , but it should be acknowledged that the relatively small numbers involved in single-center case series such as ours precludes multivariable analyses that could more definitively address this issue. Importantly, it has been repeatedly shown that living kidney donation (both related and unrelated) for FSGS results in equal or superior graft survival compared with deceased donation (6 -9) .
In addition to more clearly defining our population at risk and eliminating native renal output to facilitate early and accurate monitoring of allograft protein excretion, our clinical approach to KTx recipients with known FSGS has centered on attempts to optimize the peritransplant use of PP and, more recently, rituximab therapy. In this regard, we have taken our cues from existing and emergent reports (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) as well as from periodic review of our own clinical results. One of the most compelling goals we set during the course of our recent transplant practice was to determine whether we could strengthen the evidence that preemptive PP (followed by additional PP during the first week) is associated with reduced risk of FSGS recurrence. In contrast to reports by Gohh et al. (20) and others (17) (18) (19) , however, our results suggest that this is not the case. Furthermore, those receiving preemptive PP had similarly early recurrence compared with those who did not. Although disappointing at face value, it may be unreasonable, based on the presumed role of a persisting circulating factor (5, 10) , to consider PP as having the potential for more than a modifying effect on FSGS recurrence. Indeed, we have observed that the most severe manifestation of recurrent FSGS (primary nonfunction with failure to respond to posttransplant PP) has not occurred among those managed with a preemptive PP protocol and proteinuria has been, at least initially, responsive to prolonged courses of PP in this group.
More recently still, we administered rituximab as adjuvant therapy to PP for recurrent FSGS in four cases based on encouraging reports involving pediatric KTx recipients with both relapsed nephrotic syndrome and posttransplant lym- (21, 22) . Since these initial reports appeared, additional cases have been described with variable outcomes (see Table 5 for a summary) (23) (24) (25) (26) (27) (28) . Although some of the described cases entail striking and prolonged resolution of proteinuria after rituximab in otherwise treatment-resistant FSGS, an overall assessment of the reports indicates weak evidence at best for a broadly applicable therapeutic benefit. The most recent report by Yabu et al. (27) involving four well-defined cases of recurrent FSGS documents no clear remission after rituximab administration although one patient is described as entering a prolonged remission approximately 3 months later. The authors speculate that response to rituximab may be a characteristic of pediatric KTx recipients and, in fact, the four additional cases we report from our center were between the ages of 5 and 19 years at KTx. Although each received rituximab in the context of ongoing PP therapy, the subsequent prolonged remissions of proteinuria that occurred after discontinuation of PP represent an outcome that we had not previously encountered in this patient group. Of note, the three patients who received rituximab in the early posttransplant period did not reach nadir urine protein excretion for several months after therapy. The fourth, who had been dependent on PP for more than 2 years after initial diagnosis of recurrent FSGS and had suffered multiple prior episodes of relapse on discontinuation of PP, was given rituximab and subsequently weaned successfully from PP with no relapse thus far. This case bears a clear similarity to that reported recently by Meyer et al. (28) . Considering our cases along with those summarized in Table 5 , it seems that patients who have successfully achieved remission with rituximab have been predominantly young and that extended follow-up may be required to determine responsiveness.
In conclusion, our study highlights the persistent clinical challenges involved in providing optimal KTx care to children and adults with primary FSGS-particularly, those with clinical details indicative of a high rate of disease recurrence. Although we confirm differences in recurrence rates (and perhaps response to rituximab) between pediatric and adult KTx recipients, it is clear that graft outcomes are negatively impacted by recurrent disease across a wide age spectrum. In the absence of a true pathophysiological breakthrough, we believe that further improvements in graft outcomes for this patient group can and should be achieved by (a) adopting clear definitions of the criteria by which primary FSGS is to be diagnosed before and after KTx. (b) Developing multisite protocols that can truly assess the benefits of preemptive PP combined with rituximab among a high-risk population.
